Brief: Santhera Completes First 6-Month Period Of Pivotal Vision-DMD Trial With Vamorolone
03/03/2021 06:10
March 3 (Reuters) - Santhera Pharmaceuticals Holding AG
SANN.S :
* SANTHERA ANNOUNCES COMPLETION OF FIRST 6-MONTH PERIOD OF
PIVOTAL
VISION-DMD TRIAL WITH VAMOROLONE IN DUCHENNE MUSCULAR DYSTROPHY
Source text for Eikon: ID:nNDL9SL33b
Further company coverage: SANN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million